DOCS

As of 2026-10-26, DOCS scores 57out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. DOCS trades at $33.08, within its fair-value band.

DOCS scores 57 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 57. Its strongest factor is value at 71 (strong), where it screens cheap on the model's valuation inputs, followed by momentum at 70. The weakest is volume at 38, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 22% of the Healthcare names the model scores.

On valuation, DOCS is priced in the upper part of its recent range. The blended composite before the macro overlay was 58. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on DOCS, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where DOCS sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for DOCS runs $19.81–$41.14. Current price $33.08 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.